Plural Ring Oxygens In The Hetero Ring Patents (Class 514/463)
  • Patent number: 9839228
    Abstract: This can provide a volatile disinfectant produced by bubbling ozone gas into a volatile solvent, the volatile solvent containing at least one volatile liquid paraffin, one volatile silicone oil, or a mixture thereof as a base under stirring the volatile solvent to thereby allow the volatile solvent to contain the ozone gas, the volatile disinfectant characterized in that, when applied to an object, the volatile disinfectant inactivates pathogens on the object and then volatilizes from the object.
    Type: Grant
    Filed: September 7, 2014
    Date of Patent: December 12, 2017
    Assignee: E-TECH CO., LTD
    Inventor: Eiichi Yoshida
  • Patent number: 9592188
    Abstract: The present disclosure provides compositions and methods for treating dermatological disorders using a podophyllotoxin formulation.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: March 14, 2017
    Inventor: Yansong Liu
  • Publication number: 20150057344
    Abstract: The present invention generally relates to health benefits of natural compounds. In particular, the present invention relates peltatins, a group of natural compounds that can be used to treat, prevent or alleviate chronic inflammatory disorders. For example, the present invention concerns a composition comprising at least one peltatin for use in the treatment or prevention of chronic inflammatory disorders.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 26, 2015
    Inventors: Mohamed Nabil Bosco, Christian Darimont-Nicolau, Jalil Benyacoub
  • Publication number: 20150045425
    Abstract: The present invention relates to the field of metabolic disorders and aims to identify natural compounds that can be used effectively in this field. In particular, the present invention provides a composition comprising at least one peltatin for use in the treatment or prevention of metabolic disorders or risk factors thereof.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 12, 2015
    Inventors: Mohamed Nabil Bosco, Christian Darimont-Nicolau, Jalil Benyacoub
  • Patent number: 8946251
    Abstract: The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also applicable to treating the hot flashes, hot flushes, or night sweats associated with disease states that disrupt normal hormonal regulation of body temperature.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: February 3, 2015
    Assignee: Noven Therapeutics, LLC
    Inventor: Patricia Allison Tewes Richards
  • Publication number: 20150031759
    Abstract: Compounds, compositions, methods of making, and methods of using analogues of (?)-picropodophyllin, as well as a transgenic animal model and its use for identifying anticancer agents.
    Type: Application
    Filed: July 10, 2014
    Publication date: January 29, 2015
    Inventors: David B. Berkowitz, Sylvain Broussy
  • Patent number: 8937096
    Abstract: The present invention is a method for the treatment of mania and/or bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: January 20, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Virginia L. Smith-Swintosky, Allen B. Reitz
  • Patent number: 8877718
    Abstract: The present invention relates to naphthoquinone derivatives isolated from solid callus cultures from two species of the palaeotropical plant families Dioncophyllaceae and Ancistrocladaceae. It further relates to methods of their production as well as to their use as antiinfective and antitumoral pharmaceuticals.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: November 4, 2014
    Assignee: Julius-Maximilians-Universität Würzburg
    Inventors: Gerhard Bringmann, Stefan Rüdenauer, Reto Brun, Andreas Irmer, Ralf Bargou, Manik Chatterjee, Anastasia Voskobojnik
  • Patent number: 8865749
    Abstract: This invention is a method of killing the stealthy intra-cellular bacteria which cause many Th1 and ‘Autoimmune’ diseases.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: October 21, 2014
    Inventor: Trevor Gordon Marshall
  • Patent number: 8859527
    Abstract: Inclusion complex of deoxypodophyllotoxin of cyclodextrin, the preparation method and the use for the treatment of cancer thereof are disclosed. The inclusion complex consists of deoxypodophyllotoxin and beta-cyclodextrin derivative, wherein the molar ration of deoxypodophyllotoxin to beta-cyclodextrin derivative is 1:1-1:10. The beta-cyclodextrin derivative is sulfobutyl ether-beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: October 14, 2014
    Assignees: Zhejiang Jianfeng Pharmaceutical Holdings, China Pharmaceutical University
    Inventors: Xiong Zhu, Jinlong Huang, Baojin Wu, Houwei Luo, Zhiwu Yin, Changxuan Wu
  • Patent number: 8858991
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: October 14, 2014
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Patent number: 8859614
    Abstract: Analogs of (?)-Picropodophyllin, synthesis thereof, and uses in pharmaceuticals as inhibitors of IGF1RK.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: October 14, 2014
    Assignee: University of Nebraska—Lincoln
    Inventors: David B. Berkowitz, Sylvain Broussy
  • Patent number: 8859615
    Abstract: The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I).
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: October 14, 2014
    Inventors: Samuel J. Danishefsky, Ting-Chao Chou, Xiaoguang Lei, Heedong Yun, Fay Ng, John Hartung, Dalibor Sames
  • Patent number: 8859576
    Abstract: The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also applicable to treating the hot flashes, hot flushes, or night sweats associated with disease states that disrupt normal hormonal regulation of body temperature.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: October 14, 2014
    Assignee: Noven Therapeutics, LLC
    Inventor: Patricia Allison Tewes Richards
  • Patent number: 8853263
    Abstract: The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle sulfamide derivative and a therapeutically effective amount of one or more anticonvulsant and/or anti-epileptic agents.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: October 7, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Virginia L. Smith-Swintosky, David F. McComsey, Michael H. Parker, Allen B. Reitz, Bruce E. Maryanoff
  • Patent number: 8835123
    Abstract: Diagnostic and therapeutic methods pertaining to diseases and disorders of the breast, uterus and ovary are encompassed herein. More particularly, diagnostic methods for early detection of progenitor cells of breast, uterine, and ovarian cancers are described herein. The identification of markers for these cancer predisposing progenitor cells, which co-express the progesterone receptor (PR) and p63, provides tools and methods of use thereof that facilitate early detection of increased frequency of PR/p63 double positive (PR/p63+) progenitor cells in asymptomatic patients and thus, early detection of increased cancer risk in such patients and assessment, diagnostic stratification, and evaluation of therapeutic intervention in symptomatic patients.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: September 16, 2014
    Assignee: New York University
    Inventors: David L. Kleinberg, Mary Helen Barcellos-Hoff
  • Patent number: 8765806
    Abstract: Provided is a biocidal composition comprising 2,6-dimethyl-m-dioxane-4-ol acetate and an isothiazolinone biocidal compound. The composition is useful for controlling microorganisms in aqueous or water containing systems.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: July 1, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Ioana Annis, Jon B. Raymond, Emerentiana Sianawati
  • Patent number: 8735446
    Abstract: The invention relates to a sensory stimulant composition containing one or more of vanillin acetals represented by the general formula (1), and a flavor and fragrance composition, a beverage or food product, a fragrance or cosmetic product, a daily utensil product, an oral composition, or a pharmaceutical product containing the sensory stimulant composition with a warming sensation agent or cooling sensation substance, if necessary. Vanillin acetals represented by the general formula (1) show an excellent pungent and/or warming sensation effect and a cooling sensation-emphasizing effect.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: May 27, 2014
    Assignee: Takasago International Corporation
    Inventors: Kenya Ishida, Takashi Aida
  • Patent number: 8735393
    Abstract: The present invention provides anhydrous compositions for topical delivery of a medicament comprising (A) a penetration enhancer/solvent selected from the group consisting of alcohol, propylene glycol, or a combination thereof; (B) a humectant/solvent selected from the group consisting of polyethylene glycol, glycerin, sorbitol, xylitol, or any combination of any of the foregoing; and (C) an anhydrous vehicle. In an alternate embodiment, the present invention provides anhydrous compositions for topical delivery of a medicament which comprise (A) a penetration enhancer/solvent selected from the group consisting of alcohol, propylene glycol, or a combination thereof; (B) a humectant/solvent selected from the group consisting of polyethylene glycol, glycerin, sorbitol, xylitol or any combination of any of the foregoing; (C) an anhydrous vehicle; and (D) a medicament. Also provided are methods for topically delivering a medicament to an animal.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: May 27, 2014
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Katherine M. Burnett, Ellen S. Kurtz
  • Publication number: 20140142173
    Abstract: The present invention relates to: a pharmaceutical composition or a Nurr1 activating composition for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the composition comprises an active ingredient in the form of genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; or a functional food additive for preventing or alleviating a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the additive comprises genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; and a method for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the method comprises the step of administering the pharmaceutical composition.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 22, 2014
    Inventors: Won Gon Kim, Baek Soo Han, Kyoung Shim Kim, Kwang Soo Kim, Young Mi Kang, Yu Jin Kim, Chun Hyung Kim, Mi Jin Sohn, Hoe Yune Jung
  • Publication number: 20140128459
    Abstract: The present invention relates to solid forms of 13-(N-Boc-?-isobutylserinyl)-14-?hydroxybaccatin III 1, 14-carbonate (Ortataxel). Amorphous Form A, crystalline Form B, mixtures thereof and processes for preparing them are disclosed. Amorphous Form A is prepared by fast precipitation of Ortataxel from a mixture of acetone and water. Form A transforms in Form B when suspended and stirred in a mixture of ethanol and water for 4-8 hours. If the suspension is stirred for less than 4 hours, mixtures of Form B and Form A are obtained. Form B or mixtures of Forms A and B can also be obtained dissolving Ortataxel in a protic organic solvent, followed by addition of water.
    Type: Application
    Filed: December 10, 2013
    Publication date: May 8, 2014
    Applicant: Indena S.p.A.
    Inventors: Daniele Ciceri, Nicola Sardone, Bruno Gabetta, Maurizio Ricotti
  • Patent number: 8716231
    Abstract: The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as described herein. The present invention is further directed to methods for the treatment of pain comprising co-therapy with analgesic agent(s) and a compound of formula (I) or formula (II) as described herein.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: May 6, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Virginia L. Smith-Swintosky, Allen B. Reitz
  • Patent number: 8691867
    Abstract: The present invention is a method for the treatment of alcohol abuse and/or addiction comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and/or formula (II) as herein defined.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: April 8, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Virginia L. Smith-Swintosky, Allen B. Reitz
  • Publication number: 20140088186
    Abstract: A composition for preventing and/or treating dementia and ameliorating memory impairment and/or improving memory, comprising one or more arylnaphthalene lignan derivatives, such as Justicidin A, 5-methoxyjusticidin A, Chinensinaphthol, and a pharmaceutically-acceptable salt thereof, as active ingredient.
    Type: Application
    Filed: September 25, 2013
    Publication date: March 27, 2014
    Applicants: The Council for Scientific and Industrial Research, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Hyun Ok Yang, Sung-Kwon Chung, Hak Cheol Kwon, Jin Wook Cha, Young-Joo Kim, Gerda Fouche, Rudzani Nthambeleni, Dashnie Naidoo, Jeremiah Senabe, Vinesh Jaichand Maharaj, Eric Khorombi, Jungyeob Ham, Joon Ki Kim
  • Patent number: 8673969
    Abstract: The present invention provides compounds of general formula (3) as useful potential antitumour agents against human cancer cell lines. The present invention further provides a process for the synthesis of 4?-acrylamidopodophyllotoxin congeners of general formula (3), wherein R and R1 are an aryl group and R is selected from 3,4,5-trimethoxyphenyl or 2-methoxy phenyl and R1 is selected from the group consisting of 4-hydroxy-3-methoxyphenyl, 3-hydroxy-4-methoxyphenyl, 4-fluoro-3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 2-fluoro-5-methoxyphenyl, 2-fluoro-4-methoxyphenyl, 4-hydroxy-3-nitrophenyl, 4-methoxy-3-nitrophenyl, 4-nitrophenyl, 3-nitrophenyl, 2-nitro phenyl, 4-methoxyphenyl, 3-methoxyphenyl and 4-hydroxyphenyl.
    Type: Grant
    Filed: March 9, 2011
    Date of Patent: March 18, 2014
    Assignee: Council of Scientific & Industrial Research
    Inventors: Kamal Ahmed, Suresh Paidakula, Ashwini Kumar Banala, Adla Malla Reddy, Papagiri Venkat Reddy
  • Patent number: 8664265
    Abstract: The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: March 4, 2014
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Arno Appavoo Enose, Harish Kumar Madan, Sumit Madan, Anupam Trehan, Puneet Tyagi, Vinod Kumar Arora
  • Patent number: 8658663
    Abstract: The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also applicable to treating the hot flashes, hot flushes, or night sweats associated with disease states that disrupt normal hormonal regulation of body temperature.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: February 25, 2014
    Assignee: Noven Therapeutics, LLC
    Inventor: Patricia Allison Tewes Richards
  • Patent number: 8642602
    Abstract: The present invention relates to the discovery of an epigenetic relay pathway that controls hepatic stellate cell activation and the wound-healing response in fibrogenesis, including fibrogenesis of the injured liver. Methods of inhibiting fibrogenesis, including liver fibrogenesis and secondary disease states and conditions thereof, and in treating liver damage, including cirrhosis of the liver (which may be caused by viruses or chemicals, including alcohol), are aspects of the present invention. The methods utilize certain nucleoside compounds and/or antibodies which are optionally conjugated. Pharmaceutical compositions represent additional aspects of the invention.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: February 4, 2014
    Assignees: University of Georgia Research Foundation, Inc., University of Newcastle Upon Tyne
    Inventors: Jelena Mann, Chung K. Chu, Derek A. Mann
  • Patent number: 8637490
    Abstract: Described herein are compounds that may be selectively activated to produce active anti-cancer agents in tumor cells. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating cancer using the compounds.
    Type: Grant
    Filed: July 1, 2012
    Date of Patent: January 28, 2014
    Assignee: UWM Research Foundation, Inc.
    Inventors: Xiaohua Peng, Yunyan Kuang, Sheng Cao, Wenbing Chen, Yibin Wang
  • Publication number: 20130338117
    Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.
    Type: Application
    Filed: August 27, 2013
    Publication date: December 19, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventor: Robert P. RICCIARDI
  • Publication number: 20130331445
    Abstract: The invention related to picropodophyllin monohydrate as well as to picropodophyllin polymorph A for use in therapy, such as their use in cancer therapy.
    Type: Application
    Filed: October 7, 2011
    Publication date: December 12, 2013
    Applicant: Axelar AB
    Inventors: Mikael Bisrat, Magnus Brisander
  • Publication number: 20130317099
    Abstract: The invention relates to novel polymorphs of picropodophyllin, methods for preparing said polymorphs and pharmaceutical compositions comprising said polymorphs, as well as the use of said polymorphs in therapy such as cancer therapy.
    Type: Application
    Filed: October 7, 2011
    Publication date: November 28, 2013
    Applicant: Axelar AB
    Inventors: Mikael Bisrat, Magnus Brisander
  • Publication number: 20130303601
    Abstract: The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.
    Type: Application
    Filed: April 3, 2013
    Publication date: November 14, 2013
    Inventors: James D. McChesney, John T. Henri, Sylesh Kumar Venkataraman, Mahesh Kumar Gundluru
  • Patent number: 8575137
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: November 5, 2013
    Assignee: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • Publication number: 20130274283
    Abstract: Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.
    Type: Application
    Filed: February 11, 2013
    Publication date: October 17, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Richard A. GATTI, Liutao DU, Robert DAMOISEAUX, Chih-Hung LAI, Michael JUNG, Jin-Mo KU, Carmen BERTONI
  • Patent number: 8536196
    Abstract: Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: September 17, 2013
    Assignee: Evolva SA
    Inventors: Alexandra Santana Sorensen, Jean-Philippe Meyer, Peteris Alberts, Prathama S. Mainkar, Melya Hughes Crameri, Thierry Bonnaud, Joanne Kelleher, David Pearson
  • Publication number: 20130225672
    Abstract: The present invention provides compounds of general formula (3) as useful potential antitumour agents against human cancer cell lines. The present invention further provides a process for the synthesis of 4?-acrylamidopodophyllotoxin congeners of general formula (3), wherein R and R1 are an aryl group and R is selected from 3,4,5-trimethoxyphenyl or 2-methoxy phenyl and R1 is selected from the group consisting of 4-hydroxy-3-methoxyphenyl, 3-hydroxy-4-methoxyphenyl, 4-fluoro-3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 2-fluoro-5-methoxyphenyl, 2-fluoro-4-methoxyphenyl, 4-hydroxy-3-nitrophenyl, 4-methoxy-3-nitrophenyl, 4-nitrophenyl, 3-nitrophenyl, 2-nitro phenyl, 4-methoxyphenyl, 3-methoxyphenyl and 4-hydroxyphenyl.
    Type: Application
    Filed: March 9, 2011
    Publication date: August 29, 2013
    Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Kamal Ahmed, Suresh Paidakula, Ashwini Kumar Banala, Adla Malla Reddy, Papagiri Venkat Reddy
  • Patent number: 8501790
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: August 6, 2013
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Zachary Demko, Christopher Borella, Shoujun Chen, Lijun Sun
  • Patent number: 8497298
    Abstract: The present invention is a method for the glucose related disorders and lipid related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) or formula (II) as herein defined. The present invention is further directed to methods of treatment comprising co-therapy with an anti-diabetic agent, and anti-lipid agent and/or an anti-obesity agent.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: July 30, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Virginia L. Smith-Swintosky, Allen B. Reitz
  • Patent number: 8492567
    Abstract: The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamide, or alkyl-urea or alkyl-sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: July 23, 2013
    Assignee: Pierre Fabre Medicament
    Inventors: Thierry Imbert, Yves Guminski, Jean-Marc Barret, Anna Kruczynski
  • Publication number: 20130143959
    Abstract: The invention relates to an extract and/or one or more natural compounds from plants or parts of plants, respectively, from a genus selected from Schisandra, Illicium, Kadsura, Steganotaenia or Magnolia, for the regulation of body weight, fat loss, and/or management of obesity, in humans or in animals, methods and uses of the same and to the use of the same or mixtures in the manufacture of a pharmaceutical or nutraceutical formulation. The above can further be used to reduce one or more adverse metabolic parameters in a subject. The invention relates also to said extract and/or compound(s) in the treatment or in the preparation of a medicament for treatment of obesity, as well as their preparation. It also relates to pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s), which are useful in the regulation of body weight and/or fat loss and/or for the management of obesity.
    Type: Application
    Filed: November 19, 2012
    Publication date: June 6, 2013
    Applicant: INTERMED DISCOVERY GMBH
    Inventor: INTERMED DISCOVERY GMBH
  • Publication number: 20130090367
    Abstract: This application relates to the modulation of host cell factors required for influenza virus replication. The application relates to compounds, including nucleic acid compounds (such as, e.g., small interfering RNAs (siRNAs)) and small molecules, that target human host cell factors involved in influenza virus replication, and the use of such compounds for modulating influenza virus replication and as antiviral agents. The application also relates to methods of treating an influenza virus infection and methods of treating or preventing a symptom or disease associated with influenza virus infection, comprising administering to a subject a composition comprising a compound, such as a nucleic acid compound (e.g., an siRNA) or small molecule, that targets a human host cell factor involved in influenza virus replication.
    Type: Application
    Filed: December 10, 2010
    Publication date: April 11, 2013
    Inventors: Megan Shaw, Peter Palese, Adolfo Garcia-Sastre, Silke Stertz, John Young, Renate König, Sumit Chanda
  • Patent number: 8404869
    Abstract: Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving metabolic syndromes, comprising (a) a therapeutically effective amount of a particular compound represented by Formula 1 as defined in the specification, or isomer, prodrug, or solvate or thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: March 26, 2013
    Assignees: Mazence Inc., KT & G Co., Ltd.
    Inventors: Sang-Ku Yoo, Ku Suk Kang, Sang Woo Yoo, Taehwan Kwak
  • Publication number: 20130059018
    Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
    Type: Application
    Filed: March 11, 2011
    Publication date: March 7, 2013
    Applicants: OTSUKA PHARMACEUTICAL CO., LIMITED, GW PHARMA LIMITED
    Inventors: Daniela Parolaro, Paola Massi, Angelo Antonio Izzo, Francesca Borelli, Gabriella Aviello, Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello, Alessia Ligresti, Ruth Alexandra Ross, Lesley Ann Ford, Sharon Anavi-Goffer, Manuel Guzman, Guillermo Velasco, Mar Lorente, Sofia Torres, Tetsuro Kikuchi, Geoffrey Guy, Colin Stott, Stephen Wright, Alan Sutton, David Potter, Etienne De Meijer
  • Publication number: 20130005666
    Abstract: The NF-E2-related factor 2 (Nrf2) is a key transcriptional regulator of antioxidant defense and detoxification. To directly monitor stabilization of Nrf2 we fused its Neh2 domain, responsible for the interaction with its nucleocytoplasmic regulator, Keap1, to firefly luciferase (Neh2-luciferase). It is shown herein that Neh2 domain is sufficient for recognition, ubiquitination and proteasomal degradation of Neh2-luciferase fusion protein. The novel Neh2-luc reporter system allows direct monitoring of the adaptive response to redox stress and classification of drugs based on the time-course of reporter activation. The novel reporter was used to screen a library of compounds to identify activators of Nrf2. The most robust and yet non toxic Nrf2 activators found—nordihydroguaiaretic acid, fisetin, and gedunin-induced astrocyte-dependent neuroprotection from oxidative stress via an Nrf2-dependent mechanism.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 3, 2013
    Applicant: CORNELL UNIVERSITY
    Inventors: Rajiv RATAN, Irina GAZARYAN, Natalya A. SMIRNOVA
  • Publication number: 20120315298
    Abstract: A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.
    Type: Application
    Filed: June 15, 2012
    Publication date: December 13, 2012
    Applicant: NEXGENIX PHARMACEUTICALS, INC
    Inventors: Ruihong CHEN, Allan E. Rubenstein, Xiaodong Shen, Scott Stewart, Jin-Chen Yu
  • Publication number: 20120283281
    Abstract: The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamide, or alkyl-urea or alkyl-sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 8, 2012
    Inventors: Thierry IMBERT, Yves GUMINSKI, Jean-Marc BARRET, Anna KRUCZYNSKI
  • Patent number: 8268882
    Abstract: Disclosed are compounds based on C- and D-ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: September 18, 2012
    Assignee: Pharmagenesis, Inc.
    Inventor: John H. Musser
  • Publication number: 20120225934
    Abstract: Inclusion complex of deoxypodophyllotoxin of cyclodextrin, the preparation method and the use for the treatment of cancer thereof are disclosed. The inclusion complex consists of deoxypodophyllotoxin and beta-cyclodextrin derivative, wherein the molar ration of deoxypodophyllotoxin to beta-cyclodextrin derivative is 1:1-1:10. The beta-cyclodextrin derivative is sulfobutyl ether-beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin.
    Type: Application
    Filed: October 1, 2010
    Publication date: September 6, 2012
    Inventors: Xiong Zhu, Jinlong Huang, Baojin Wu, Houwei Luo, Zhiwu Yin, Changxuan Wu
  • Patent number: 8242161
    Abstract: The present invention provides for, inter alia, novel topical formulations comprising at least one 1-N-arypyrazole derivative and amitraz and to methods for treating, controlling, or preventing parasite infestations on mammals or birds The inventive formulations include spot-on, pour-on or spray formulations and may include a further ectoparasiticide, such as an IGR compound, an avermectin or milbemycin derivative, or a pyrethroid insecticides, and anthelmintics, such as benzimidazoles and imidazothiazoles. The inventive formulation provides a larger duration of parasite control at a faster rate of control. The inventive formula remains effective up to three months from the first application. Moreover, the inventive formulations prevent tick attachment to the animal, thereby providing protection against tick borne diseases. The ectoparasites which may be controlled, treated or prevented by the present invention includes ticks, fleas, mites, mange, lice, mosquitoes, flies and cattle grubs.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: August 14, 2012
    Assignee: Merial Limited
    Inventors: Albert Boeckh, Luiz Gustavo Cramer, Mark D. Soll